This is the second of our annual Talent Equity® reports analysing the performance of biotech Boards, CEOs and Chairs in Europe and the USA.
In this report, we’ve taken a forensic look at the investment performance of the leading biotech companies over the last three years and the elements that have contributed to the performance of their Boards:
- Share ownership
- Succession planning
- Diversified composition / Gender diversity
As always, by analysing the industry’s leaders, we’ve focused on best practice to learn more about how to improve Board performance across the sector and the companies that they lead. This year we’ve added insight on the differences between high-performing public company Boards on different stock exchanges.
Read the full report here: